Doctor of Osteopathy Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Alexandra Bowles

General Practice Cincinnati, OH Doctor of Osteopathy

NPI 1073071478 CMS profile 10089262

7730 Montgomery Rd, Cincinnati, OH 45236

Open in the dashboard

General payments

$5,862

178 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexandra Bowles of Cincinnati, OH is reported in the CMS Open Payments database as having received $5,862 across 178 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,706 59
2024 General $1,764 60
2023 General $483 16
2022 General $728 17
2021 General $1,180 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexandra Bowles
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Alexandra Bowles were reported at $1,706. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Alexandra Bowles General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $1,180 $93 $30–$272 $132
2022 $728 $103 $36–$279 $149
2023 $483 $106 $34–$276 $160
2024 $1,764 $114 $39–$290 $164
2025 $1,706 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,225 74 payments
  2. Sun Pharmaceutical Industries Inc. $819 21 payments
  3. Incyte Corporation $386 11 payments
  4. Novartis Pharmaceuticals Corporation $355 11 payments
  5. Amgen Inc. $269 4 payments
  6. E.R. Squibb & Sons, L.L.C. $234 7 payments
  7. Galderma Laboratories, L.P. $220 4 payments
  8. Lilly USA, LLC $184 5 payments
  9. Janssen Biotech, Inc. $178 6 payments
  10. Janssen Scientific Affairs, LLC $125 1 payment
  11. Other $867 34 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,549 173 payments
  2. Education $288 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $25 1 payment
Products named General payments · program years 2021–2025
  1. SKYRIZI $692 21 payments
  2. BOTOX $659 12 payments
  3. ILUMYA $515 11 payments
  4. OPZELURA $386 11 payments
  5. RINVOQ $354 15 payments
  6. Winlevi $328 9 payments
  7. Otezla $269 4 payments
  8. TREMFYA $264 5 payments
  9. COSENTYX $245 6 payments
  10. SOTYKTU $234 7 payments
  11. Other $1,794 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

88

Median for Dermatology: 534

Drug cost

$807

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 30 $464
Mupirocin Generic 26 $176
Triamcinolone Acetonide Generic 18 $120
Cephalexin Generic 14 $47

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 37 billing codes

Paid by Medicare

$59,865

Medicare's payments for the services billed

Medicare patients

267

Average age 74

Services billed

1,645

183 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 41%
Ischemic heart disease 22%
Osteoporosis 22%
Cancer 18%
Depression 17%
Diabetes 14%
Atrial fibrillation 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
  • Incyte Corporation $324
$324 — —
SKYRIZI
  • AbbVie, Inc. $221
$221 — —
BOTOX
  • AbbVie, Inc. $133
$133 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $123
$123 — —
OLUMIANT
  • Lilly USA, LLC $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

178 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record